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Abstract
Background: Patients with psoriasis have increased prevalence of coronary risk factors and limited recent results have
suggested that these risk factors are undertreated in patients with psoriasis. This may contribute to the increased risk of
cardiovascular diseases observed in patients with psoriasis.
Objective: To examine the pharmacological treatment of coronary risk factors in patients with severe psoriasis treated with
biologic agents in a real-world setting.
Methods and Findings: Medical history of patients with severe psoriasis treated with biologic agents in the time period
2007–09 was retrieved from a Danish nationwide registry (DERMBIO). Individual-level linkage of nationwide administrative
registries of hospitalizations, concomitant medications, and socioeconomic status was performed to gain insights into the
use of pharmacological treatment. A total of 693 patients (mean age 46.1612.7 years, 65.7% male) with severe psoriasis
treated with biologic agents were identified. Hypertension, hypercholesterolemia, and diabetes mellitus were identified in
16.6%, 9.2%, and 6.7% of cases, respectively. Patients with severe psoriasis were significantly less likely to receive
cardiovascular pharmacotherapy compared to age, sex, and coronary risk factor matched controls. In psoriatic patients with
hypertension 27.7% received no antihypertensive pharmacotherapy. Patients with dyslipidemia received cholesterol-
lowering medications in 55.8% of cases and patients with diabetes mellitus received angiotensin converting enzyme
inhibitors/angiotensin II receptor blockers and cholesterol-lowering medications in 42.1% and 23.7% of cases, respectively.
Similar results were found for the subset of patients with .1 coronary risk factor and for high risk patients with established
atherosclerotic disease.
Conclusion: This nationwide study of patients with severe psoriasis demonstrated substantial undertreatment of coronary
risk factors. Increased focus on identifying cardiovascular risk factors and initiation of preventive cardiovascular
pharmacotherapy in patients with psoriasis is warranted.
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Introduction
Patients with psoriasis have increased prevalence of classical
coronary risk factors, including hypertension, hypercholesterol-
emia, and diabetes mellitus and increased risk of cardiovascular
disease, e.g., myocardial infarction and stroke [1,2,3,4,5,6,7].
Screening practices, treatment, and clinical control aimed at
coronary risk factors and disease may be inadequate in patients
with other chronic diseases [8,9] and very recent results from a
highly selected population of patients participating in phase III
randomized trials with ustekinumab, a therapeutic anti-interleukin
(IL)-12/IL-23p40 monoclonal antibody, demonstrated marked
undertreatment and underdiagnosis of coronary risk factors in
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factors may contribute to the increased risk of cardiovascular
disease in patients with psoriasis. To examine the current practice
regarding the pharmacological treatment of coronary risk factors
in patients with psoriasis in a real-world setting we examined the
pharmacological management of these risk factors in patients with
severe psoriasis treated with biologic agents between 2007 and
2009.
Methods
Ethics
The study was approved by The Danish Data Protection
Agency and the DERMBIO steering committee. Data at the
individual case level was made available by the national registers in
anonymized form. Registry studies do not require ethical approval
in Denmark. The corresponding author had full access to the data
and take responsibility for its integrity.
Data sources
In Denmark all citizens are provided with a unique social
security number at birth enabling linkage across registries. Medical
history of patients with severe psoriasis selected for treatment with
biologic agents was retrieved from a nationwide Danish registry
(DERMBIO), a nationwide Danish database of patients with
psoriasis treated with biologic agents. [12] Registration of patients
with psoriasis treated with biologic agents is mandatory. From
DERMBIO information registered on the date of subject database
entry, psoriasis activity and severity index score, baseline history of
hypertension, hypercholesterolemia and diabetes mellitus, and
previous systemic antipsoriatic treatment and biologic treatment
were recorded. Patients with psoriasis identified with hypertension,
hypercholesterolemia, and diabetes mellitus were age- and sex
matched with 4 individuals with corresponding coronary risk
factors (hypertension, hypercholesterolemia, and diabetes mellitus)
from the general population. All medications dispensed from
pharmacies were obtained from the National Prescription Registry
(the Danish Registry of Medicinal Product Statistics), wherein all
dispensed prescriptions from Danish pharmacies has been
recorded since 1995. Comorbidity, including ischemic heart
disease (International classification of diseases 10th revision
[ICD-10] codes: I20–I25), cerebrovascular disease (ICD-10: I60–
I69), peripheral arterial disease (ICD-10: I70–I74), hypertension
(ICD-10: I10), hypercholesterolemia (ICD-10: E78), and type II
diabetes mellitus (ICD-10: I11) was obtained from the Danish
National Patient Register in which all hospital admissions,
diagnoses, and invasive procedures have been recorded since
1978. Individual-level linkage with these nationwide administra-
tive registries of hospitalizations and dispensed prescriptions were
used to assess treatment of coronary risk factors. Results were
summarized as means with standard deviations for continuous
data and counts and percentages for categorical data. Differences
in pharmacological treatment were assessed by chi-square test. A
two-sided p-value ,0.05 was considered statistically significant.
Outcome measures
Prescriptions claimed up to 6 months prior to study inclusion
and 6 months after inclusion for drugs with therapeutic indications
aimed at coronary risk factors and cardiovascular diseases
including platelet inhibitors (anatomical therapeutic chemical
classification [ATC] code: B01AC), beta-blockers (C07), angio-
tensin-converting enzyme inhibitors (ACE-Is)/angiotensin II
receptor blockers (ARBs) (C09), calcium antagonist (C08), loop
diuretics (C03C), thiazide diuretics (C03A), cholesterol-lowering
drugs (C10A), and glucose-lowering drugs (A10).
Results
A total of 693 patients (mean age 46.1612.7 years, 65.7% male)
with severe psoriasis treated with biologic agents were identified
and baseline characteristics of the study population are presented
in Table 1. Coronary risk factors, including hypertension,
hypercholesterolemia, and diabetes mellitus were identified in
16.6%, 9.2%, and 6.7%, respectively
Patients with psoriasis and coronary risk factors received
significantly less evidence based pharmacotherapy compared to
age, sex, and coronary risk factor matched individuals from the
general population (Tables 2 and 3). In psoriatic patients with
hypertension 27.7% received no pharmacotherapy. Along this
line, patients with dyslipidemia only received cholesterol-lowering
medication in 55.8% of cases. Patients with diabetes mellitus
received ACE-Is)/ARBs and cholesterol-lowering medication in
42.1% and 23.7% of cases, respectively. Pharmacologic treatment
in patents with .1 cardiovascular risk factor and secondary
prophylaxis in the small subset of patents with manifest
atherosclerotic disease showed a similar pattern of infrequent use
Table 1. Baseline characteristics of patients with psoriasis.
Patients with psoriasis n=693
Age/years (mean, standard deviation) 612.7
Female (%) 238 (34.3)
Male (%) 455 (65.7)
PASI* score (mean, standard deviation) 13.068.1
Psoriatic arthritis 85 (12.3)
Established atherosclerotic disease** 6 (0.9)
Coronary risk factors
Hypertension 94/565 (16.6)
Hypercholesterolemia 52/565 (9.2)
Diabetes mellitus 38/565 (6.7)
Previous systemic psoriasis
treatment
Methotrexate 469 (67.7)
Psoralen+UVA*** 125 (18.0)
Cyclosporine 161 (23.2)
Retinoids 116 (16.7)
Climate therapy 60 (8.7)
Biologic agents
Adalimumab 279 (40.3)
Alefacept 2 (0.3)
Efalizumab 39 (5.6)
Etanercept 264 (38.1)
Infliximab 64 (9.2)
Tocilizumab 2 (0.3)
Ustekinumab 42 (6.1)
Information not recorded 1 (0.1)
*PASI; psoriasis activity and severity index.,
**Established atherosclerosis; ischemic heart disease, cerebrovascular disease,
peripheral vascular disease.
***UVA; ultraviolet A light.
doi:10.1371/journal.pone.0036342.t001
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5). Assessment of pharmacological treatment 6 months after the
index date indicated similar patterns of drug use, however beta
blocker use generally decreased, e.g., 12.8% and 2.1% for
hypertension at baseline and after 6 months, respectively
(Tables 3, 4, 5).
Discussion
In a nationwide study of patients with psoriasis treated with
biologic agents the proportion of patients with coronary risk
factors treated with cardio-protective drugs was generally low and
this finding was consistent for all examined coronary risk factors.
Also, in the subset of patients with .1 identified cardiovascular
risk factor and in those with established atherosclerosis, including
ischemic heart disease, cerebrovascular disease, and peripheral
artery disease the proportion of patients receiving cardio-
protective treatment was low. The results add to recent evidence
indicating that patients with psoriasis are subject to inadequate
pharmacological treatment of coronary risk factors and the
observed undertreatment may contribute to the increased risk of
adverse cardiovascular events seen in these patients.
In general, adequate treatment of coronary risk factors,
including hypertension, hypercholesterolemia, and diabetes melli-
tus remains a challenge in clinical practice [13,14,15]. It is well-
established that psoriasis is associated with increased risk of
cardiovascular disease, and increased prevalence of risk factors
and shared autoimmune and inflammatory pathways between
psoriasis and cardiovascular disease may contribute to this
association [1,2,3,4,5,6,7]. This has sparked an ongoing discussion
of the need for increased awareness of this risk by treating
physicians (general practitioners, dermatologists, cardiologists etc.)
and for dedicated guidelines on coronary risk factor management
in patients with psoriasis [16]. Moreover, recent studies have
examined the risk of cardiovascular events in patients with
psoriasis according to the Framingham cardiovascular risk
prediction score and documented that a high proportion of
patients with psoriasis were at substantially increased risk and
making them potential candidates for pharmacological cardiovas-
cular primary prophylaxis [11,17]. In agreement with these
findings, previous results from our group demonstrated that
patients with severe psoriasis and/or psoriatic arthritis carried an
absolute and relative risk of cardiovascular disease comparable to
that of patients with diabetes mellitus [6]. Indeed, recent Danish
guidelines recommended that cardiovascular primary prophylaxis
in patients with severe psoriasis and/or psoriatic arthritis should
correspond to the treatment offered to patients with diabetes
mellitus [18]. These Danish guidelines largely mirror recent
guidelines of the European League Against Rheumatism on the
management of cardiovascular risk in patients with inflammatory
arthritis, including psoriatic arthritis [19].
Regardless of augmented scientific focus on the association
between psoriasis and increased cardiovascular risk, however, a
very recent study of patients with psoriasis participating in phase
III randomized trials with ustekinumab found that patients with
coronary risk factors were subject to suboptimal pharmacological
treatment [11]. The present results from a real-world clinical
setting are in agreement with this observation and suggest that
such undertreatment may pose a general problem in patients with
Table 2. Medical management of coronary risk factors in
patients with psoriasis and age- and sex matched controls.
Patients with
psoriasis Controls P value
Hypertension n=94 n=376
ACE-Is/ARBs* 50 (53.2) 235 (62.5) 0.09
Beta-blockers 12 (12.8) 153 (40.7) ,0.001
Calcium antagonists 25 (26.6) 154 (41.0) 0.01
Thiazide diuretics 16 (17.0) 120 (31.9) 0.004
Any anti-hypertensive drug 68 (72.3) 327 (87.0) ,0.001
Hypercholesterolemia n=52 n=208
Cholesterol-lowering drugs 29 (55.8) 136 (65.4) 0.19
Diabetes mellitus n=38 n=152
ACE-Is/ARBs* 16 (42.1) 94 (61.8) 0.03
Platelet inhibitors 9 (23.7) 44 (29.0) 0.52
Cholesterol-lowering drugs 9 (23.7) 87 (57.2) ,0.001
*ACE-1; angiotensin-converting enzyme inhibitor, ARB; Angiotensin II receptor
blocker.
doi:10.1371/journal.pone.0036342.t002
Table 3. Medical management of coronary risk factors.
Pharmacotherapy at baseline (%) Pharmacotherapy at 6 months (%)
Hypertension n=94
ACE-Is/ARBs* 50 (53.2) 47 (50.0)
Beta-blockers 12 (12.8) 2 (2.1)
Calcium antagonists 25 (26.6) 21 (22.3)
Thiazide diuretics 16 (17.0) 14 (14.9)
Any anti-hypertensive drug 68 (72.3) 58 (61.1)
Hypercholesterolemia n=52
Cholesterol-lowering drugs 29 (55.8) 29 (55.8)
Diabetes mellitus n=38
ACE-Is/ARBs* 16 (42.1) 14 (36.8)
Platelet inhibitors 9 (23.7) 9 (23.7)
Cholesterol-lowering drugs 9 (23.7) 12 (31.6)
*ACE-1; angiotensin-converting enzyme inhibitor, ARB; Angiotensin II receptor blocker.
doi:10.1371/journal.pone.0036342.t003
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blockers was expected since beta-blockers may cause psoriatic
exacerbations [20], the explanation for low use of other cardio-
protective drugs is less apparent. Indeed, the reasons for lack of
initiation and/or adherence to cardiovascular pharmacotherapy
may be more dependent on inadequate knowledge and imple-
mentation of current guidelines by physicians, physician- or
patient-driven worries about poly-pharmacy, reliance on non-
pharmacological treatments, and other less-defined physician and
patient preferences, than on evidence-based factors, e.g., treatment
denied because of adverse drug reactions. Irrespective of the
underlying reasons, it is an apparent paradox that psoriasis
patients selected for treatment with expensive biologic agents and
regularly evaluated by physicians (as is well-established in Den-
mark) seemingly elude treatment of coronary risk factors. Less
than one percent of patients in the present study had established
atherosclerotic disease and the results thus mainly reflect
inadequate cardiovascular primary prophylaxis. On the other
hand, our previous study of the prognosis following first-time
myocardial infarction in Danish patients with psoriasis indicated
that the post myocardial infarction pharmacological treatment
(secondary prophylaxis) was adequate and non-differential be-
tween patients with and without psoriasis, respectively [21].
However, that study was not powered to address differences in
treatment related to psoriasis disease severity and did not
specifically focus on the initiation and adherence to cardiovascular
secondary prophylaxis.
In 2008 the US National Psoriasis Foundation recommended
that all patients with psoriasis should be referred to a general
practitioner for cardiovascular risk factor assessment, including
family history, annual blood pressure measurement, biennial
screening for obesity, and lipid and glucose screening every 2nd or
5th year for patients with or without classical coronary risk factors,
respectively [16,22]. Of note, it has also recently been suggested
that patients with psoriasis are inadequately screened for coronary
risk factors [10]. The current report of pharmacological
undertreatment of risk factors may therefore in fact underestimate
the true magnitude of this problem. In addition, it has been
suggested that current risk assessment tools, e.g., the Framingham
risk score underestimate the true risk in patients with chronic
inflammatory disease, e.g., systemic lupus erythematosus [23].
This is further supported by numerous studies demonstrating
increased carotid intima-media thickening, endothelial dysfunc-
tion, and coronary calcification in patients with psoriasis in the
absence of established atherosclerotic disease [24,25,26]. Thus the
distinction between cardiovascular primary and secondary pro-
phylaxis in these patients may be argued to be somewhat arbitrary.
The following limitations should be acknowledged. The study
included patients with severe psoriasis treated with biologic agents
and the results may not apply to other subsets of patients with
psoriasis, e.g., patients treated with topical treatment or non-
biologic systemic anti-inflammatory treatment. Information on
non-pharmacological treatment of cardiovascular risk factors was
unavailable. Also, information on blood pressure, cholesterol
levels, blood glucose levels were absent and we were therefore
unable to calculate formal cardiovascular risk scores, e.g.,
Framingham risk score. We had no information about the reasons
for lack of cardiovascular pharmacotherapy.
Important strengths of the present study included the nation-
wide coverage, the direct comparison with age, sex, and risk factor
matched controls, and the contemporary real-world clinical
setting. The use of nationwide registries of hospitalization data
and dispensed prescriptions from all pharmacies in Denmark
where healthcare is readily accessible and essentially free of charge
minimized selection bias related to sex, age, socioeconomic status,
healthcare insurance status and job situation.
Conclusion
This nationwide study of patients with severe psoriasis treated
with biologic agents demonstrated that a high proportion of
patients with identified coronary risk factors received little or no
cardio-protective pharmacotherapy. The results indicate a need
for increased awareness of cardiovascular risk and cardiovascular
Table 4. Cardiovascular prophylaxis in patients with .1 coronary risk factor (n=40).*
Pharmacotherapy at baseline (%) Pharmacotherapy at 6 months (%)
ACE-Is/ARBs** 19 (47.5) 25 (62.5)
Beta-blockers 6 (15.0) 2 (5.0)
Platelet inhibitors 10 (25.0) 11 (25.5)
Cholesterol-lowering drugs 17 (42.5) 21 (52.5)
*Coronary risk factor; hypertension, hypercholesterolemia, diabetes mellitus.
**ACE-I; angiotensin-converting enzyme inhibitor, ARB; Angiotensin II receptor blocker.
doi:10.1371/journal.pone.0036342.t004
Table 5. Secondary cardiovascular prophylaxis in patients with established atherosclerotic disease (n=6).*
Pharmacotherapy at baseline (%) Pharmacotherapy at 6 months (%)
ACE-Is/ARBs** 3 (50.0) 2 (50.0)
Beta-blockers 2 (33.3) 0 (0.0)
Cholesterol-lowering drugs 4 (66.7) 4 (66.7)
Platelet inhibitors 5 (83.3) 3 (50.0)
*Previous hospitalization with a diagnosis of ischemic heart disease, cerebrovascular disease, or peripheral vascular disease.
**ACE-I; angiotensin-converting enzyme inhibitor, ARB; Angiotensin II receptor blocker.
doi:10.1371/journal.pone.0036342.t005
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trials of intensified cardiovascular risk factor management in these
patients are urgently needed.
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